WILMINGTON, Del. – AstraZeneca has released positive full results from its Phase IIIb BATURA trial, marking a significant advancement in asthma treatment. The trial showed that Airsupra (albuterol/budesonide), used as-needed, significantly outperformed standard albuterol rescue therapy in patients with mild asthma. These findings were simultaneously published in the New England Journal of Medicine and presented at the American Thoracic Society (ATS) 2025 International Conference.
Airsupra demonstrated statistically significant and clinically meaningful improvements across all primary and secondary endpoints compared to albuterol alone. Notably, it reduced the risk of severe asthma exacerbations by 47%, underscoring its potential as a new standard of care.
The BATURA study builds on previous Phase III trials, MANDALA and DENALI, reinforcing the growing body of evidence supporting Airsupra as a superior rescue treatment across the spectrum of asthma severity.
The findings come as the Global Initiative for Asthma (GINA) has moved away from recommending albuterol-only treatment, which has dominated asthma care in the U.S. for more than 50 years.
With these results, AstraZeneca positions Airsupra as a breakthrough innovation capable of reshaping asthma management, potentially improving outcomes for millions who rely on fast-acting relief.
